

DAFTAR PUSTAKA

- Abrahamsohn, PA., Dos Santos, MF., Zorn, TMT., 2005. *Basic histology text and atlas, 11th edition*. McGraw-Hills.
- Akslen, L.A., Angelini, S., Straume, O., Bachmann, I.M., Molven, A., et al, 2005. *BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival*. Journal Investigative Dermatology 125, pp :312–317.
- Akslen, L.A., Puntervoll, H., Bachmann, I.M., Straume, O., Vuhahula, E., et al, 2008. *Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma*. Melanoma Research. 18, pp:29–35
- American Cancer Society: Cancer Facts and Figures, 2018. Atlanta.
- Amin, MB., Edge, SB., Brookland, RK., Jessup, JM., Greene, FL., et al, 2017. *AJCC Cancer Staging Manual, Eight Edition*. www.cancerstaging.org. pp : 563-581.
- Bachmann, I.M., Ladstein, R.G., Straume, O., Naumov, G.N., Akslen, L.A., 2008. *Tumor necrosis is associated with increased alphavbeta3integrin expression and poor prognosis in nodular cutaneous melanomas*. BioMed Central Cancer 8, p : 362.
- Barnhill, R.L., Piepkorn, M., Busam, K.J., 2014. *Pathology of Melanocytic Nevi and Melanoma, 3rd ed*. Springer-Verlag, Berlin Heidelberg.
- Behjati, S., Tarpey, P.S., 2013. *What is next generation sequencing?* Arch Dis Child Educ Pract Ed 98, pp: 236–238
- Carlino, M.S., Haydu, L.E., Kakavand, H., Menzies, A.M., Hamilton, A.L., et al, 2014. *Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma*. British Journal of Cancer 111, pp: 292–299.
- Colombino, M., Capone, M., Lissia, A., Cossu, A., Rubino, C., et al, 2012. *BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma*. Journal of Clinical Oncology. 30, pp : 2522–2529.
- Curtin, J.A., Fridlyand, J., Kageshita, T., Patel, H.N., Busam, K.J., et al., 2005. *Distinct Sets of Genetic Alterations in Melanoma*. The New England Journal of Medicine. 353, pp : 2135–2147.

- Elder, D. E., Massi, D., Scolyer, R. A., and Willemze, R., 2018. *WHO classification of skin tumours. International Agency for Research on Cancer (IARC), Lyon, France* pp : 65-77
- Ellerhorst, J.A., Greene, V.R., Ekmekcioglu, S., Warneke, C.L., Johnson, M.M., et al., 2011. *Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Human Cancer Biology* 17, pp : 229–235
- Garbe, C., Peris, K., Hauschild, A., Saiag, P., Middleton, M., et al., 2016. *Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016. Europe Journal Cancer* 63, pp : 201–217.
- Goel, V.K., Lazar, A.J.F., Warneke, C.L., Redston, M.S., Haluska, F.G., 2006. *Examination of Mutations in BRAF, NRAS, and PTEN in Primary Cutaneous Melanoma. Journal of Investigative Dermatology* 126, pp: 154–160.
- Chairil, H., Fransisca, M., and Siregar, Chairani., 2012. *Patologi Molekuler*. Penerbit Fakultas Kedokteran Universitas Indonesia, Jakarta. pp : 7-114.
- Homsy, J., Sabet, M., Messina, J., and Daud, A., 2011. *Cutaneous melanoma: prognostic factors. Surgical Oncology of North America* 20, pp : 145-163.
- Jakob, J.A., Bassett, R.L., Ng, C.S., Curry, J.L., Joseph, R.W., Alvarado, G.C., et al., 2012. *NRAS mutation status is an independent prognostic factor in metastatic melanoma. National Institute of Health* 118, pp: 4014–4023
- Johnson, D.B., and Puzanov, I., 2015. *Treatment of NRAS-mutant melanoma. Current Treatment Options Oncol* pp : 16-15
- Jones, A.M., Ferguson, P., Gardner, J., Rooker, S., Sutton, T., et al., 2016. *NRAS and EPHB6 mutation rates differ in metastatic melanomas of patients in the North Island versus South Island of New Zealand. Oncotarget* 7, 41017–41030
- Kaufman, H.L., and Mehnert, J.M., 2016. *Melanoma, Cancer Treatment and Research*. Springer International Publishing
- Kim, S.Y., and Yun, S.J., 2016. *Cutaneous Melanoma in Asians. Chonnam Medical Journal* 52, pp: 185–193
- Kumar, V., Abbas, A.K., and Aster, J.C., 2015. *Robbins Basic Pathology 9th ed*. Elsevier. pp : 172-174

- Macaluso, M., Russo, G., Cinti, C., Bazan, V., Gebbia, N., 2002. *Ras family genes: An interesting link between cell cycle and cancer*. Journal of Cellular Physiology 192, pp: 125–130
- Malumbres, M., and Pellicer, A., 1998. *RAS pathways to cell cycle control and cell transformation*. Frontiers in Bioscience 3, pp : 887-912
- Muñoz-Couselo, E., Adelantado, E., Vélez, C., Soberino-García, J., Perez-Garcia, J., 2017. *NRAS-mutant melanoma: Current challenges and future prospect*. OncoTargets and Therapy Volume 10, pp : 3941–3947.
- National Comprehensive Cancer Network (NCCN), 2018, *Melanoma (Version 1.2018)*
- Posch, C., Vujic, I., Monshi, B., Sanlorenzo, M., Weihsengruber, F., et al., 2016. *Searching for the Chokehold of NRAS Mutant Melanoma*. Journal of Investigative Dermatology 136, pp: 1330-1336
- Rinonce, H.T., Aji, R.P.M., Hayati, N., Pudjohartono, M.F., Kameswari, B., et al., 2019. *Low BRAF V600 mutation prevalence in primary skin nodular melanoma in Indonesia: a real-time PCR detection among Javanese patients*. BMC Proc 13.
- Saldanha, G., Potter, L., DaForno, P., Pringle, J.H., 2006. *Cutaneous Melanoma Subtypes Show Different BRAF and NRAS Mutation Frequencies*. American Association for Cancer Research 12, pp: 4499–4505
- Sheen, Y.-S., Liao, Y.-H., Lin, M.-H., Chen, J.-S., Liao, J.-Y., et al., 2017. *Clinicopathological features and prognosis of patients with de novo versus nevus-associated melanoma in Taiwan*. Plos One 12
- Shen, S., Wolfe, R., McLean, C.A., Haskett, M., Kelly, J.W., 2014. *Characteristics and Associations of High-Mitotic-Rate Melanoma*. JAMA Dermatology 150, 1048.
- The Global Cancer Observatory., 2019. GLOBOCAN fact sheets: melanoma skin.
- Thomas, N.E., Edmiston, S.N., Alexander, A., Groben, P.A., Parrish, E., et al., 2015. *Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients with Higher-Risk Primary Melanoma*. JAMA Oncology 1, pp : 359–368.
- Uguen, A., Talagas, M., Costa, S., Samaison, L., Paule, L., et al., 2015. *NRAS Q6R, BRAF V600E immunohistochemistry: a concomitant tool for mutation screening in melanomas*. Diagnostic Pathology 10, pp : 1–10

- Woodman, S.E., Lazar, A.J., Aldape, K.D., Davies, M.A., 2012. *New Strategies in Melanoma: Molecular Testing in Advanced Disease*. Clinical Cancer Research 18, pp : 1195–1200
- Yaman, B., Akalin, T., Kandiloğlu, G., 2015. *Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma*. American Journal Dermatopathology 37, pp : 389–397
- Yilmaz, I., Gamsizkan, M., Kucukodaci, Z., Berber, U., Demirel, D., et al., 2015. *BRAF, KIT, NRAS, GNAQ and GNA11 mutation analysis in cutaneous melanomas in Turkish population*. Indian Journal Pathology Microbiology 58, pp:279–284.